Literature DB >> 29876649

A novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development.

Laura Kranaster1, Suna Su Aksay2, Jan Malte Bumb3, Carolin Hoyer4, Christine Jennen-Steinmetz5, Alexander Sartorius2.   

Abstract

Early identification of patients at high risk for an unfavorable outcome to ECT during the course might be beneficial because it provides an opportunity for timely intensification or optimization of stimulus conditions. We aimed to develop a new Seizure Quality Index (SQI) that delivers a clinical relevant outcome prediction early in the treatment course and can be used within common clinical setting. An observational study was conducted. Patients (n = 86) with a depressive episode and the clinical decision for ECT (right unilateral, brief pulse) were included, and several ictal parameters derived from the second ECT session and the clinical outcome of the patients were documented. Optimal cut-off points for five different domains of ictal adequacy for younger and older patients for the prediction of "non-response" and "non-remission" based on seizure quality was determined by the Youden Index and a sum score was built. Logistic regression analyses tested the predictive power of derived models. For both outcome variables "non-response" and "non-remission", the logistic regression models were statistically significant, albeit for remission only for subjects below the age of 65 years (χ2 = 17.9, p = 0.001) and (χ2 = 6.4, p = 0.020), respectively. The models correctly classified 87.2% (non-response) and 50.0% (non-remission) of the cases. ROC curve analysis showed an AUC of 0.87 (non-response) and 0.70 (non-remission). In elderly patients (> 65), no such model could be established due to a response rate of 100%. Our data provide promising, clinically relevant results about the prediction of response to ECT at an early stage for patients with depression.

Entities:  

Keywords:  Depression; Electroconvulsive therapy; Outcome; Prediction

Mesh:

Year:  2018        PMID: 29876649     DOI: 10.1007/s00406-018-0910-6

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  53 in total

1.  The effects of electroconvulsive therapy on quantitative electroencephalograms. Relationship to clinical outcome.

Authors:  H A Sackeim; B Luber; G P Katzman; J R Moeller; J Prudic; D P Devanand; M S Nobler
Journal:  Arch Gen Psychiatry       Date:  1996-09

2.  Burst suppression: a more valid marker of postictal central inhibition?

Authors:  Laura Kranaster; Peter Plum; Carolin Hoyer; Alexander Sartorius; Heiko Ullrich
Journal:  J ECT       Date:  2013-03       Impact factor: 3.635

Review 3.  Electroconvulsive Therapy in Geriatric Psychiatry: A Selective Review.

Authors:  Justin P Meyer; Samantha K Swetter; Charles H Kellner
Journal:  Psychiatr Clin North Am       Date:  2017-12-13

4.  Bitemporal Versus High-Dose Unilateral Twice-Weekly Electroconvulsive Therapy for Depression (EFFECT-Dep): A Pragmatic, Randomized, Non-Inferiority Trial.

Authors:  Maria Semkovska; Sabine Landau; Ross Dunne; Erik Kolshus; Adam Kavanagh; Ana Jelovac; Martha Noone; Mary Carton; Sinead Lambe; Caroline McHugh; Declan M McLoughlin
Journal:  Am J Psychiatry       Date:  2016-02-19       Impact factor: 18.112

Review 5.  Augmentation strategies in electroconvulsive therapy.

Authors:  Colleen Loo; Brett Simpson; Ross MacPherson
Journal:  J ECT       Date:  2010-09       Impact factor: 3.635

6.  Convulsive threshold differences in right unilateral and bilateral ECT.

Authors:  W V McCall; F E Shelp; R D Weiner; S Austin; J Norris
Journal:  Biol Psychiatry       Date:  1993-11-01       Impact factor: 13.382

7.  EEG manifestations during ECT: effects of electrode placement and stimulus intensity.

Authors:  M S Nobler; H A Sackeim; M Solomou; B Luber; D P Devanand; J Prudic
Journal:  Biol Psychiatry       Date:  1993-09-01       Impact factor: 13.382

8.  Seizure expression during electroconvulsive therapy: relationships with clinical outcome and cognitive side effects.

Authors:  Tarique D Perera; Bruce Luber; Mitchell S Nobler; Joan Prudic; Christopher Anderson; Harold A Sackeim
Journal:  Neuropsychopharmacology       Date:  2004-04       Impact factor: 7.853

9.  Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors.

Authors:  Aazaz U Haq; Adam F Sitzmann; Mona L Goldman; Daniel F Maixner; Brian J Mickey
Journal:  J Clin Psychiatry       Date:  2015-10       Impact factor: 4.384

10.  Electroconvulsive Treatment: Hypotheses about Mechanisms of Action.

Authors:  Roar Fosse; John Read
Journal:  Front Psychiatry       Date:  2013-08-27       Impact factor: 4.157

View more
  4 in total

1.  Overlooking the obvious? Influence of electrolyte concentrations on seizure quality parameters in electroconvulsive therapy.

Authors:  Michael Belz; Isabel Methfessel; Miriam Spang; Matthias Besse; Thorsten Folsche; Caspar Stephani; David Zilles
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-07-17       Impact factor: 5.270

2.  Accounting for symptom heterogeneity can improve neuroimaging models of antidepressant response after electroconvulsive therapy.

Authors:  Benjamin S C Wade; Gerhard Hellemann; Randall T Espinoza; Roger P Woods; Shantanu H Joshi; Ronny Redlich; Udo Dannlowski; Anders Jorgensen; Christopher C Abbott; Leif Oltedal; Katherine L Narr
Journal:  Hum Brain Mapp       Date:  2021-08-13       Impact factor: 5.038

3.  Changes in seizure duration during acute course electroconvulsive therapy.

Authors:  James Luccarelli; Thomas H McCoy; Stephen J Seiner; Michael E Henry
Journal:  Brain Stimul       Date:  2021-06-11       Impact factor: 9.184

4.  Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality.

Authors:  Alexander Sartorius; Juliane Beuschlein; Dmitry Remennik; Anna-Maria Pfeifer; Sebastian Karl; Jan Malte Bumb; Suna Su Aksay; Laura Kranaster; Christoph Janke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-07-22       Impact factor: 5.270

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.